PDCD1 and neoplasm: Notably, pharmacological inhibition of DUSP18 with lumacaftor, in combination with anti-PD-1 (programmed cell death 1 (PDCD1; also known as PD-1) immunotherapy, significantly suppressed tumor growth in vivo [54].